|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 310.60 DKK | +1.32% |
|
+5.11% | -4.50% |
| 13/02 | Hedge funds bet big against Hims & Hers Health before Wegovy showdown, Hazeltree data shows | RE |
| 13/02 | Novo Nordisk's Wegovy Tablet Reaches 38,000 New Prescriptions in the US | FW |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 14TCr | 18TCr | 23TCr | 29TCr | 31TCr | |||||
Total Revenues | 14TCr | 18TCr | 23TCr | 29TCr | 31TCr | |||||
Cost of Goods Sold, Total | 2.37TCr | 2.84TCr | 3.58TCr | 4.36TCr | 5.44TCr | |||||
Gross Profit | 12TCr | 15TCr | 20TCr | 25TCr | 25TCr | |||||
Selling General & Admin Expenses, Total | 4.11TCr | 5.07TCr | 6.16TCr | 6.74TCr | 6.79TCr | |||||
R&D Expenses | 1.72TCr | 2.33TCr | 3.1TCr | 4.01TCr | 4.62TCr | |||||
Other Operating Expenses | -46Cr | -108.5Cr | -12Cr | -48Cr | 4.5Cr | |||||
Other Operating Expenses, Total | 5.78TCr | 7.29TCr | 9.25TCr | 11TCr | 11TCr | |||||
Operating Income | 5.93TCr | 7.56TCr | 10TCr | 14TCr | 14TCr | |||||
Interest Expense, Total | -29Cr | -38Cr | -54Cr | -164Cr | -420.7Cr | |||||
Interest And Investment Income | 23Cr | 24Cr | 106.9Cr | 183.8Cr | 126.9Cr | |||||
Net Interest Expenses | -5.8Cr | -14Cr | 53Cr | 20Cr | -293.8Cr | |||||
Income (Loss) On Equity Invest. | -2.4Cr | -19Cr | 8.1Cr | -1.7Cr | -1.7Cr | |||||
Currency Exchange Gains (Loss) | 34Cr | -465.1Cr | 165.2Cr | -102.3Cr | 600.7Cr | |||||
Other Non Operating Income (Expenses) | -12Cr | -18Cr | -20Cr | -29Cr | -24Cr | |||||
EBT, Excl. Unusual Items | 5.95TCr | 7.05TCr | 11TCr | 14TCr | 14TCr | |||||
Restructuring Charges | - | - | - | - | -936.6Cr | |||||
Merger & Related Restructuring Charges | -12Cr | -5.1Cr | - | -98Cr | - | |||||
Gain (Loss) On Sale Of Investments | 30Cr | -59Cr | 3.7Cr | -1.7Cr | 7.1Cr | |||||
Asset Writedown | -57Cr | -76Cr | -141.4Cr | -1.06TCr | -359.4Cr | |||||
Other Unusual Items | - | - | - | - | - | |||||
EBT, Incl. Unusual Items | 5.91TCr | 6.91TCr | 10TCr | 13TCr | 13TCr | |||||
Income Tax Expense | 1.13TCr | 1.35TCr | 2.1TCr | 2.62TCr | 2.81TCr | |||||
Earnings From Continuing Operations | 4.78TCr | 5.55TCr | 8.37TCr | 10TCr | 10TCr | |||||
Net Income to Company | 4.78TCr | 5.55TCr | 8.37TCr | 10TCr | 10TCr | |||||
Net Income - (IS) | 4.78TCr | 5.55TCr | 8.37TCr | 10TCr | 10TCr | |||||
Net Income to Common Incl Extra Items | 4.78TCr | 5.55TCr | 8.37TCr | 10TCr | 10TCr | |||||
Net Income to Common Excl. Extra Items | 4.78TCr | 5.55TCr | 8.37TCr | 10TCr | 10TCr | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 10.4 | 12.26 | 18.67 | 22.67 | 23.06 | |||||
Basic EPS - Continuing Operations | 10.4 | 12.26 | 18.67 | 22.67 | 23.06 | |||||
Basic Weighted Average Shares Outstanding | 459.32Cr | 453.06Cr | 448.28Cr | 445.39Cr | 444.3Cr | |||||
Net EPS - Diluted | 10.37 | 12.22 | 18.62 | 22.63 | 23.03 | |||||
Diluted EPS - Continuing Operations | 10.37 | 12.22 | 18.62 | 22.63 | 23.03 | |||||
Diluted Weighted Average Shares Outstanding | 460.62Cr | 454.46Cr | 449.48Cr | 446.3Cr | 444.77Cr | |||||
Normalized Basic EPS | 8.09 | 9.72 | 14.79 | 19.47 | 20.18 | |||||
Normalized Diluted EPS | 8.07 | 9.69 | 14.75 | 19.43 | 20.15 | |||||
Dividend Per Share | 5.2 | 6.2 | 9.4 | 11.4 | 11.7 | |||||
Payout Ratio | 45.06 | 45.57 | 37.96 | 43.71 | 50.53 | |||||
American Depositary Receipts Ratio (ADR) | 0 | 0 | 0 | 0 | 0 | |||||
Supplemental Items | ||||||||||
EBITDA | 6.36TCr | 8.09TCr | 11TCr | 15TCr | 15TCr | |||||
EBITA | 6.02TCr | 7.7TCr | 11TCr | 14TCr | 15TCr | |||||
EBIT | 5.93TCr | 7.56TCr | 10TCr | 14TCr | 14TCr | |||||
EBITDAR | 6.49TCr | 8.24TCr | 11TCr | - | - | |||||
Effective Tax Rate - (Ratio) | 19.17 | 19.6 | 20.05 | 20.6 | 21.53 | |||||
Total Current Taxes | 1.33TCr | 1.82TCr | 2.5TCr | 3.23TCr | 2.9TCr | |||||
Total Deferred Taxes | -194.5Cr | -463.1Cr | -401.1Cr | -605.1Cr | -88Cr | |||||
Normalized Net Income | 3.72TCr | 4.4TCr | 6.63TCr | 8.67TCr | 8.96TCr | |||||
Interest on Long-Term Debt | - | - | - | - | - | |||||
Non-Cash Pension Expense | 14Cr | 18Cr | 13Cr | 16Cr | 13Cr | |||||
Supplemental Operating Expense Items | ||||||||||
Selling and Marketing Expenses | 3.7TCr | 4.62TCr | 5.67TCr | 6.21TCr | 6.27TCr | |||||
General and Administrative Expenses | 405Cr | 446.7Cr | 485.5Cr | 527.6Cr | 516Cr | |||||
Research And Development Expense From Footnotes | 1.78TCr | 2.4TCr | 3.24TCr | 4.81TCr | 5.2TCr | |||||
Net Rental Expense, Total | 130.3Cr | 149.1Cr | 183.2Cr | - | - | |||||
Imputed Operating Lease Interest Expense | 16Cr | 17Cr | 30Cr | - | - | |||||
Imputed Operating Lease Depreciation | 114.02Cr | 131.9Cr | 153.11Cr | - | - | |||||
Stock-Based Comp., Other (Total) | 104Cr | 153.9Cr | 214.9Cr | 228.9Cr | 143.5Cr | |||||
Total Stock-Based Compensation | 104Cr | 153.9Cr | 214.9Cr | 228.9Cr | 143.5Cr |
- Stock Market
- Equities
- NOVO B Stock
- Financials Novo Nordisk A/S
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















